Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had ...

Larimar will continue the open label extension study in Friedreich’s ataxia with results expected in Q4 this year.

Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data ...

U.S. stocks were mostly higher, with the Dow Jones index gaining around 50 points on Tuesday. Shares of XPeng Inc. XPEV rose ...

Larimar (LRMR) said the FDA has removed a partial clinical hold on its nomlabofusp clinical program following a review of ...

(RTTNews) - Larimar Therapeutics, Inc. (LRMR) Tuesday announced that FDA has removed the partial clinical hold placed on its nomlabofusp or CTI-1601, a clinical program targeting treatment of patients ...

Shares of Larimar Therapeutics, Inc.. LRMR rose sharply in today's pre-market trading after the company announced that the FDA removed the partial clinical hold previously placed on the nomlabofusp ...

Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Larimar Therapeutics (LRMR – Research Report), retaining the price ...

By Stephen Nakrosis Shares of Larimar Therapeutics were trading higher in after-hours action Monday, following news the U.S. Food and Drug Administration ...

Leerink Partners raised the price target for the Larimar Therapeutics Inc (NASDAQ:LRMR) stock to “an Outperform”. The rating was released on April 03, 2024, according to finviz. The research report ...

Asian stock markets today closed in the red. China’s Shanghai Composite Index (SHCOMP) closed down -0.42% and Japan’s Nikkei 225 Stock Index (NIK) closed down -0.31%.

Stock futures were little changed on Tuesday with consumer spending in focus, as a slew of earnings from retailers were due. Expected results from Lowe's, Macy's, AutoZone and Urban Outfitters may ...